130 related articles for article (PubMed ID: 38763751)
1. Computational Estimation of Residues Involving Resistance to the SARS-CoV-2 Main Protease Inhibitor Ensitrelvir Based on Virtual Alanine Scan of the Active Site.
Mizuno A; Nakayoshi T; Kato K; Kurimoto E; Oda A
Biol Pharm Bull; 2024; 47(5):967-977. PubMed ID: 38763751
[TBL] [Abstract][Full Text] [Related]
2. Virtual Alanine Scan of the Main Protease Active Site in Severe Acute Respiratory Syndrome Coronavirus 2.
Nakayoshi T; Kato K; Kurimoto E; Oda A
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576002
[TBL] [Abstract][Full Text] [Related]
3. Visualizing the Active Site Oxyanion Loop Transition Upon Ensitrelvir Binding and Transient Dimerization of SARS-CoV-2 Main Protease.
Kovalevsky A; Aniana A; Coates L; Ghirlando R; Nashed NT; Louis JM
J Mol Biol; 2024 Jul; 436(13):168616. PubMed ID: 38762033
[TBL] [Abstract][Full Text] [Related]
4. Insight into crystal structures and identification of potential styrylthieno[2,3-
El Bakri Y; Ahmad B; Saravanan K; Ahmad I; Bakhite EA; Younis O; Al-Waleedy SAH; Ibrahim OF; Nafady A; Mague JT; Mohamed SK
J Biomol Struct Dyn; 2024 May; 42(8):4325-4343. PubMed ID: 37318002
[TBL] [Abstract][Full Text] [Related]
5. pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity.
Al Adem K; Ferreira JC; Fadl S; Rabeh WM
J Biol Chem; 2023 Feb; 299(2):102790. PubMed ID: 36509143
[TBL] [Abstract][Full Text] [Related]
6. Ensitrelvir Fumaric Acid: First Approval.
Syed YY
Drugs; 2024 Jun; 84(6):721-728. PubMed ID: 38795314
[TBL] [Abstract][Full Text] [Related]
7. Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan.
Doi A; Ota M; Saito M; Matsuyama S
Emerg Infect Dis; 2024 Jun; 30(6):1289-1291. PubMed ID: 38669127
[TBL] [Abstract][Full Text] [Related]
8. Novel cyclohexanone compound as a potential ligand against SARS-CoV-2 main-protease.
Basu S; Veeraraghavan B; Ramaiah S; Anbarasu A
Microb Pathog; 2020 Dec; 149():104546. PubMed ID: 33011363
[TBL] [Abstract][Full Text] [Related]
9. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
10. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
Refaey RH; El-Ashrey MK; Nissan YM
Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
[TBL] [Abstract][Full Text] [Related]
11. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
[TBL] [Abstract][Full Text] [Related]
14. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
15. Depicting the inhibitory potential of polyphenols from
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
[TBL] [Abstract][Full Text] [Related]
16. Unmasking the Conformational Stability and Inhibitor Binding to SARS-CoV-2 Main Protease Active Site Mutants and Miniprecursor.
Kovalevsky A; Coates L; Kneller DW; Ghirlando R; Aniana A; Nashed NT; Louis JM
J Mol Biol; 2022 Dec; 434(24):167876. PubMed ID: 36334779
[TBL] [Abstract][Full Text] [Related]
17. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations.
Shaji D; Yamamoto S; Saito R; Suzuki R; Nakamura S; Kurita N
Biophys Chem; 2021 Aug; 275():106608. PubMed ID: 33962341
[TBL] [Abstract][Full Text] [Related]
18. Cysteine focused covalent inhibitors against the main protease of SARS-CoV-2.
Paul AS; Islam R; Parves MR; Mamun AA; Shahriar I; Hossain MI; Hossain MN; Ali MA; Halim MA
J Biomol Struct Dyn; 2022 Mar; 40(4):1639-1658. PubMed ID: 33047658
[TBL] [Abstract][Full Text] [Related]
19. Utility of Coproporphyrin-I Determination in First-in-Human Study for Early Evaluation of OATP1B Inhibitory Potential Based on Investigation of Ensitrelvir, an Oral SARS-CoV-2 3C-Like Protease Inhibitor.
Watari R; Sawada H; Hashimoto H; Kasai Y; Oka R; Shimizu R; Matsuzaki T
J Pharm Sci; 2024 Mar; 113(3):798-805. PubMed ID: 37742997
[TBL] [Abstract][Full Text] [Related]
20. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
